Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNG | P07510 | 1/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CHRND | Q07001 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6015160 | 0.88 | HPGD (0.34) | ALDH1A1NPC1POLBRAB9AALKBH5 | |
| SCHEMBL34956 | 0.84 | TUBB1 (0.37) | ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL29373037 | 0.84 | TUBB1 (0.37) | ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL20599343 | 0.84 | TUBB1 (0.37) | ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL7117533 | 0.81 | TUBB1 (0.37) | ALDH1A1NPC1POLBRAB9A | |
| SCHEMBL27176003 | 0.80 | GABRA1 (0.46) | GABRA1SIGMAR1 | |
| SCHEMBL6207683 | 0.80 | — | — | |
| SCHEMBL5231765 | 0.80 | GABRA1 (0.46) | GABRA1SIGMAR1 | |
| SCHEMBL6015169 | 0.80 | KMT2A (0.35) | — | |
| SCHEMBL27526471 | 0.79 | PDE4A (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425342-A4 | NOVEL SYMMETRICAL SUBSTITUTED BENZALDEHYDE ALDITOL DERIVATIVES AND COMPOSITIONS AND ARTICLES CONTAINING SAME | MILLIKEN & CO (US) | 2005-01-05 | — | — | EP | claimed |
| EP-1425342-A2 | NOVEL SYMMETRICAL SUBSTITUTED BENZALDEHYDE ALDITOL DERIVATIVES AND COMPOSITIONS AND ARTICLES CONTAINING SAME | Milliken & Company (US) | 2004-06-09 | — | — | EP | claimed |
| US-20030127631-A1 | Novel symmetrical halogenated and alkylated alditol derivatives and compositions and articles containing same | ANDERSON JOHN D (US) | 2003-07-10 | — | — | US | claimed |
| US-20030008951-A1 | Novel symmetrical halogenated and alkylated alditol derivatives and compositions and articles containing same | MILLIKEN & COMPANY | 2003-01-09 | — | — | US | claimed |
| WO-2002077086-A2 | NOVEL SYMMETRICAL SUBSTITUTED BENZALDEHYDE ALDITOL DERIVATIVES AND COMPOSITIONS AND ARTICLES CONTAINING SAME | MILLIKEN & COMPANY (US) | 2002-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008951-A1 | Novel symmetrical halogenated and alkylated alditol derivatives and compositions and articles containing same | ADH1C, ADH1A, ALDOA | CYP1A2 3329/4885CYP3A4 4062/4885CYP2D6 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.